TRIUMF and CNL form strategic partnership to enable ground-breaking cancer treatment

​TRIUMF, Canada's particle accelerator centre, and Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, are pleased to announce that they have agreed to pursue a strategic partnership around the commercial production of Actinium-225, a rare medical isotope that has the potential to serve as the basis of new ground-breaking cancer treatments.

An alpha-emitting isotope with a short half-life, Actinium-225 can be combined with a protein or antibody that specifically targets cancer cells, creating a revolutionary treatment that is extremely effective at killing cancer cells without doing damage to surrounding, healthy cells.

To read more please visit: https://www.eurekalert.org/pub_releases/2018-09/t-tac092618.php

Source: EurekAlert